DexCom ( DXCM -2.62%) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

Maintaining stable glucose levels is essential for your overall health, whether or not you have diabetes. Here's ...

Insurance coverage is just one catalyst for the stock. DexCom would benefit if it can increase the life usage of its products ...

Stelo was launched this year and could be an underrated growth catalyst. It could make DexCom's products accessible to a broader market, and thus significantly expand the company's prospects ...

With the company's market cap of $28 billion today, it's important to recognize that DexCom (NASDAQ: DXCM) is already one of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

The more patients within DexCom's installed base of CGM customers, the more attractive it is for other companies to make their diabetes-centered products and services compatible with DexCom's.